TABLE 5.

MAC-ELISA W/S and S/W ratios for highly cross-reactive samples and the correlation with PRNT results

Specimena	PRNT90b		VLP S/W or W/S ratioc				Interpretationd
			Mutant		WT
	SLEV	WNV	S/W	W/S	S/W	W/S
17	81,920	2,560	2.16	0.46	1.69	0.59	SLEV-s
18	81,920	2,560	2.24	0.45	4.22	0.24	SLEV-s
40	20,480	320	4.22	0.24	4.33	0.23	SLEV-s
108	40,960	5,120	1.82	0.55	3.38	0.30	SLEV-s
82	1,280	10	6.64	0.15	1.39	0.72	SLEV-s
6	640	20	6.80	0.15	2.13	0.47	SLEV-s
35	2,560	640	3.12	0.32	2.93	0.34	SLEV-s
3	160	20	2.52	0.40	1.36	0.73	SLEV-s
91	160	1,280	0.18	5.62	0.77	1.30	WNV-s
101	40	1,280	0.12	8.10	0.13	7.61	WNV-s
105	20	320	0.23	5.18	0.14	7.37	WNV-s
64	80	640	0.26	3.91	0.14	7.10	WNV-s
84	20	640	0.10	10.06	0.07	14.08	WNV-s
38	80	5,120	0.11	9.22	0.39	2.59	WNV-s
33	40	2,560	0.09	10.90	0.12	8.63	WNV-s
15	10	1,280	0.07	13.36	0.07	14.53	WNV-s
116	10	160	0.36	2.76	0.18	5.61	WNV-s
56c	1,280	160	1.43	0.70	0.94	1.07	SLEV-s
103	5,120	2,560	0.96	1.04	0.74	1.34	WNV-s
50	NDe	80	0.34	2.98	0.28	3.60	WNV-s

^aThe values shown in boldface and italics indicate samples that exhibited conflicting results between WT and mutant antigens and/or could not be PRNT confirmed.

^bPRNT₉₀, titers represent 90% plaque reduction endpoints reported by the DRL.

^cValues represent ratios of SLEV P/N to WNV P/N and vice versa as described in Materials and Methods. The higher of the two ratios for both WT and mutant VLPs in both MAC-ELISAs are shown in boldface.

^d-s, secondary infection.

^eND, not done.